LGVN · Longeveron Inc.
AI read · Bad for LGVN
The AI's read
The Phase 2b ELPIS II trial did not meet its main measure of right ventricular ejection fraction at Month 12, removing evidence that laromestrocel helps heart function in HLHS. A small trial size (40 infants) and a measured difference of −0.7 percentage points with p=0.8336 show no measurable benefit on the study's primary endpoint. Given Longeveron's small market cap and early-stage status, that result is a setback for the program and the company's near-term clinical value.